AlloSure scores rose a median of 91 days before detection of dnDSA.5
AlloSure elevations (≥0.5%) were associated with a nearly 3-fold elevation in the detection of future dn-DSA.5
NEW DATA FROM THE ADMIRAL STUDY – DOWNLOAD THE LANDMARK PUBLICATION
Assessing Dd-cfDNA Monitoring Insights of Renal Allografts with Longitudinal Surveillance (ADMIRAL).
The largest prospective cohort of kidney transplant recipients followed for three years with over 200 biopsy-paired dd-cfDNA results.5
AlloSure differentiates the absence of rejection* from TCMR and ABMR.5
AlloSure scores rose a median of 91 days before detection of dnDSA.5
AlloSure elevations (≥0.5%) were associated with a nearly 3-fold elevation in the detection of future dn-DSA.5
*Injury defined in ADMIRAL as: Out of range tacrolimus, BK viremia, dnDSA positive, urinary tract infection, proteinuria, allograft rejection, and recurrent FSGS.
Persistently elevated AlloSure (> 1 result, >= 0.5%) has a nearly 2-fold increase in risk of >25% decline in patients’ eGFR over 3 years.5 No statistical significance within first year.
Risk of clinical and subclinical rejection increases with higher AlloSure score.5-7
Relative Change Value
In addition to the absolute value, the delta/RCV between results can be indicative of allograft injury:
AlloSure testing schedule follows established clinical rationale.
Fast result turnaround time: under three days after blood draw.
The AlloSure Routine Testing Schedule (ARTS) is based on a recommendation from the DART study. All testing should be performed when medically necessary, in accordance with the treating physician’s independent medical judgment.10
A Surveillance Solution
The first analytically and clinically validated donor derived cell-free DNA (dd-cfDNA) test developed for transplant patients with a targeted SNP assay across all somatic chromosomes.
The ONLY dd-cfDNA service clinically validated for surveillance.
An Early Marker of Injury and Rejection for Kidney Transplant Patients
Broad utility in:
Fast turnaround time of results:
Your Dedicated Partner in Transplant Care
AlloSure isn’t just a test. CareDx supports our providers and patients by providing dedicated Patient Care Managers to facilitate appointment scheduling and blood draw logistics at no additional cost.*
Services
*CareDx provides specimen collection through mobile phlebotomists as part of its laboratory service so patients should not have additional out of pocket expenses beyond any coinsurance/deductibles required by their health plans for the test.
Watch the AlloSure specimen collection and shipping video and download step by step instructions.
Multi-modality surveillance. Comprehensive monitoring for kidney transplant patients, combining dd-cfDNA and gene expression profiling.
1 Hart, A. et al. OPTN/SRTR 2017 Annual Data Report: Kidney. Am J Transplant 2019; 19 ( Suppl 2): 19–123.
2 Botev R et al. Clin J Am Soc Nephrol 2009; 4:899–906.
3 Bloom RD et al. J Am Soc Nephrol 2017; 28:2221–2232.
4 Seeto, R., et. al. Biophys Rev. 2020;12(4):917-924. doi:10.1007/s12551-020-00713-5.
5 Bu L. et. al. Kidney International. 2021 Dec doi: https://doi.org/10.1016/j.kint.2021.11.034.
6 Bloom RD et al. J Am Soc Nephrol 2017; 28:2221–2232.
7 Stites E, et al. J Am Transplant, 2020; 00:1-8.
8 Bromberg JS et al. J Appl Lab Med. 2017; 2:309–321.
9 Bu L. et. al. Kidney International. 2021 Dec doi: https://doi.org/10.1016/j.kint.2021.11.034.
10 Pai A, Swan JT, Wojciechowski D, et al. Ann Transplant. 2021;26:e932249. Published 2021 Jul 2. doi:10.12659/AOT.93224.
